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Summarv
This thesis presents the results of some investigations concerning the
bioanalysis and pharmacokinetics (including biotransformation) of thiazi-
namium methylsulphate (Multergan@;. The drug is a phenothiazine
derivative with a quaternary ammonium group in the molecule. Because of
its antihistaminic and anticholinergic properties, the drug is in use for
patients suffering from generalized obstructive lung diseases.
In Part I, called "A profile of the drug under study", some analytical
chemical, physico-chemical and pharmacological data of thiazinamium
methylsulphate are dealt with, which are related to its bioanalysis and
pharmacokinetics.
Part II is entitled "Bioanalysis".
ln Chapter 1 the general principles and a few theoretical aspects of the ion
pair extraction method are discussed. Various applications and possibilities
are mentioned and a review based on the literature is given, of the analysis
of about 100 drugs using this method. Special attention is paid to the
usefulness of the method for the isolation of drugs and drug metabolites in
body fluids.
ln Chapter 2 the development of a sensitive and selective method for the
quantitative determination of thiazinamium cations in plasma, urine, bile
and saliva is described. The procedure is based on ion pair extraction of the
quaternary ammonium compound with iodide as counter ion. Optimum
extraction conditions were established on the basis of the extraction
constant and the constant for side reaction. The ion pair extraction was
followed by gas chromatography with alkali flame ionization detection
("nitrogen detector"). Thiazinamium sulphoxide cations, which was found
to be the only metabolite in humans, do not interfere in the present
procedure. Its sensitivity allows the determination of plasma concentra-
tions as they are obtained following the administration of therapeutic doses
of the drug.
ln Chapter J the development of a method for the isolation from urine and
bile and quantitative determination of thiazinamium sulphoxide cation is
described. The isolation method was based on column chromatography
with Amberlite XAD-2@. followed by two-dimensional thin-layer chroma-
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tography. The spots were visualized by immersion in an oxidative mixture
and quantitation was done by measuring the transmission of the spots with
a "flying spot" densitometer.
In Part III, called "Pharmacokinetics", the biopharmaceutical and pharma-
cokinetic studies, including biotransformation and excretion are described.
Chapter 1 contains some general remarks on bioavailability. Definitions of
the absolute and the relative bioavailability are given and some methods for
determining them are described.
ln Chapter 2 the pharmacokinetics of thiazinamium cations after intra-
venous injection in humans are discussed. It appeared that the data
observed fitted well into a two-compartment open model. Pharmacokinetic
parameters were calculated using the NAFFIT-I and NONLIN pro-
grammes and the results obtained with both programmes were compared.
A short c-phase (distribution phase) with a mean half-life of about 6 min.
was found. The apparent volume of distribution of the central compart-
ment was approximately 20 L The B-phase (elimination phase) had a much
longer half-life (approximately 300 to 600 min.) and the apparent volume
of distribution of the peripheral compartment was to the order of 200 to 300
l. A large interindividual variation was found, particularly in the data of the
p-phase.
ln Chapter 3 the pharmacokinetics following intramuscular injection are
discussed. The absolute bioavailability during the time of the experiment
was 1000/0. The absorption from the muscle was very fast. Peak plasma
concentrations were generally seen at about 10 min. after the injection was
given. Injection technique, the injection site and the capillary blood flow
seemed to be important factors in relation to the final profile of the plasma
concentration-time curve. The value for the half-life in the c-phase was
approximately 20 min. and the apparent volume of distribution for the
central compartment was 40 to 601. During the B-phase the half-life was 300
to 600 min. and the apparent volume of distribution was 200 to 400 L
Chapter 4 deals with the bioavailability of the drug after oral administra-
tion. Thiazinamium cations, in spite of the relatively high molecular weight
and the presence of a quaternary ammonium group, can be absorbed from
the gastrointestinal tract. Although the bioavailability was low (to the order
of 100/o), the plasma concentration-time curve showed a long-lasting
plateau value which ensured therapeutic plasma concentration for at least
three to six hours, provided that a sufficiently large dose is given. At the end
of the observation period (seven hours) the plasma concentrations had not
yet fallen to a zero concentration. A substantial interindividual variation
and a lower intraindividual variation in the bioavailability was reported.
ln Chapter 5 the bioavailability observed after rectal administration is
discussed. Two suppository bases were investigated, namely Witepsol H-15
and a polyethylene glycol mixture (1500/4000 in a rat io of 1:2). I t  was
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shown, that thiazinamium cations could be absorbed from the human
rectum. The best results were obtained with Witepsol H-15, with which the
relative bioavailability was of the same order of magnitude as after oral
administration, but the peak plasma concentrations appeared earlier in the
case of rectal administration (after about 60 min.) and in general the curve
had already declined to zero within seven hours. Interindividual variation
was also similar to that obtained after oral administration. After the
application of the drug in the polyethylene glycol base, very low plasma
concentrations were found and the bioavailability was almost negligible.
Attempts to increase the absorption of thiazinamium by applying the drug
as an ion pair were unsuccessful: the absorption of thiazinamium iodide
and thiazinamium salicylate was even poorer or only as good as that of the
methylsulphate.
ln Chapter 6some general remarks are made on the biotransformation and
excretion of quaternary ammonium compounds, especially those also
containing a phenothiazine group.
Chapter Tdeals with the results of a qualitative study on biotransformation
and excretion of thiazinamium cations. Thiazinamium sulphoxide was
found to be the only metabolite in humans. Neither ring-hydroxylation
products nor demethylation products (e.g. promethazine) could be detec-
ted. Thiazinamium sulphoxide was found both in urine and bile.
In the successive chapters the rate and the extent of the excretion of the
unchanged drug and the sulphoxide are discussed as obtained following
different routes of administration.
ln Chapter 8 it is reported that after an intravenous injection about 41.40lo
of the dose was excreted, unchanged, in the urine. The excretion was very
rapid and almost complete within eight hours. About 9.20/o f the dose was
excreted in the urine in the form of thiazinamium sulphoxide cations, which
gave a mean rat io between unchanged rug and metabol i te of 1:0.22.
Chapter 9 describes the excretion of thiazinamium cations and thiazina-
mium sulphoxide cations after giving the drug by an intramuscular in-
jection. Three different doses were used. After a dose of 6.25 mg or 12.5 mg
the excretion was essentially complete within eight hours, but this was not
the case after the administration of a dose of 25.0 mg. No correlation could
be found between the urine production or pH and the amount of drug
excreted in urine. About 400/o f the dose was excreted unchanged and about
100/o f the dose in the form of the sulphoxide. The ratio between the
amounts of unchanged drug and metabolite was a rather constant value in
each patient, but substantial interindividual variations were observed. In a
study involving bile-fistula patients it was found that both thiazinamium
cations and thiazinamium sulphoxide cations are excreted to a considerable
extent in bile. The amount of unchanged drug was almost equal to that in
the urine but the amount of sulphoxide was slightly higher (ratio about
1 :0.42\.
ln Chapter /0 it is shown that the biotransformation and excretion pattern
after oral administration are considerably different from those after
parenteral administration. The individual renal clearance values were
calculated. The mean value was 256 + 136(S.D.) ml, /min.,  which is
considerably higher than the value for glomerular filtration, based on
creatinine clearance. This is an indication of the occurrence of an active
excretion process (tubular secretion). Hepatic clearance (biotransforma-
tion and biliary excretion of unchanged drug) accounted for 537 +
495(S.D.) mllmin. There existed a correlation between the value of hepatic
clearance and the amount of sulphoxide in urine, whereas the hepatic
clearance and bioavailability were negatively correlated. The ratio between
the unchanged rug and the metabolite in urine was now 1 :0.94 which was
substantially different from that found after intramuscular injection in the
same patients ( 1 : 0.20). This is an indication of a "first pass effect". It was
calculated that about half of the absorbed amount of thiazinamium cations
was metabolized during the first liver passage.
The fate of thiazinamium cations after rectal administration is described in
Chapter 11, where particular attention was paid to suppositories with
Witepsol H-15 as base. Within the first seven hours of the study, about 850/o
of the totally excreted amount of unchanged drug was found in the urine.
Within 24 hours the excretion was complete and about 38.80/o f the dose
was excreted in the unchanged form whereas about 30.40/o was excreted as
sulphoxide. This gave a mean ratio between unchanged drug and sulphoxi-
de in the urine of 1 : 0.78 which was substantially different from that after
intramuscular injection in the same individuals (about 1 :0.24). This
difference has been explained by assuming a "first pass effect". It was
calculated that about 34.50/o of the absorbed amount of drug was subjected
to biotransformation during the first liver passage, which was of the same
order of magnitude as found after oral administration. This led to the
conclusion that the "first pass effect" of thiazinamium cations can not be
avoided by giving the drug rectally.
ln Chapter 12 some results are reported on the correlation between the
plasma concentration of thiazinamium cations and the heart rate. Special
attention was paid to the question of how far monitoring of the heart rate
can be of help in determining the bioavailability of thiazinamium
methylsulphate after oral administration for example. Some correlation
between the plasma concentration and the heart rate was found. This
correlation was better when dealing with higher plasma concentrations and
accordingly greater changes in the heart rate, and was possibly due to
inaccuracy of the method of monitoring the heart rate. However, it
appeared to be possible to obtain a rough impression of the order of
magnitude of the relative bioavailability of the drug after oral administra-
tion by calculating it from the areas under the heart rate-time curves,
obtained after oral and intramuscular administration.
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Finally in Chapter 1J the distribution of rsS-ringlabellecl thiazrnamrum
methylsulphate has been studied by means of whole body autoradiography
in a squirrel monkey and in mice. In the monkey, in "steady state", high
accumulations of radioactivity were found in the three main organs of
excretion of the drug (liver, kidneys and intestines). High concentrations of
radioactivity were also observed in organs with high amounts of acetyl-
choline receptors such as the ganglia, skeletal muscles (myocard) and ciliary
bodies, and in the glandular tissue (salivary glands, hypophysis, thyroid
gland and pancreas). On the other hand no radioactivity was seen in the
central  nervous system, suggest ing that thiazinamium cat ions cannot pass
the "blood-brain barrier". After intramuscular injection of the drug in mice,
it was found that the absorption started rapidly, but six hours after the
injection, a considerable residual amount was stil l present at the site of
injection. In pregnant mice high concentrations of radioactivity were
observed in the placenta, but only low amounts were found in the liver and
the kidneys of the foetuses, which implies that with thiazinamium cations,
placenta transfer can occur, although to a low extent and at a low rate. The
results of an identical study with the tertiary analogue, r5S-promethazine
hydrochloride, were discussed briefly.
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